Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-

1 Jan 2008

Abstract excerpt

BACKGROUND: More than 50% of patients with myelodysplastic syndromes present cytogenetic aberrations at diagnosis. Partial or complete deletion of the long arm of chromosome 5 is the most frequent abnormality. The aim of this study was to apply fluorescence in situ hybridization of 5q31 in patients diagnosed with de novo myelodysplastic syndromes in whom conventional banding cytogenetics study had shown a normal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Myeloid Leukemia Treatments
Share to Genomic variations and chromosomal abnormalities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18591625
DOI: 10.3324/haematol.13012

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-PMID 18591625Read ↗

Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridization reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukemia.Semantic proximity Read ↗

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Semantic proximity Read ↗

Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?Semantic proximity Read ↗

Fluorescence In Situ Hybridization Testing for −5/5q, −7/7q, +8, and del(20q) in Primary Myelodysplastic Syndrome Correlates With Conventional Cytogenetics in the Setting of an Adequate StudySemantic proximity Read ↗

Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/AMLSemantic proximity Read ↗

The utility of fluorescence in situ hybridization analysis in diagnosing myelodysplastic syndromes is limited to cases with karyotype failureSemantic proximity Read ↗

FISH and SNP-A karyotyping in myelodysplastic syndromes: improving cytogenetic detection of del(5q), monosomy 7, del(7q), trisomy 8 and del(20q).Semantic proximity Read ↗

Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.Semantic proximity Read ↗

Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGHSemantic proximity Read ↗

Duplication within chromosome 5q characterized by fluorescence in situ hybridization.Semantic proximity Read ↗

Detection of monosomy 7 in interphase cells of patients with myeloid disorders.Semantic proximity Read ↗

Loss of both CSF1R (FMS) alleles in patients with myelodysplasia and a chromosome 5 deletion.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.